Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // August 2nd, 2011 // 7:17 am
Hello, everyone, and how are you this morning? A shiny day is unfolding here on the Pharmalot corporate campus and what better way to celebrate than with a cup of stimulation? Our flavor today is Southern Pecan. You are invited to join us, of course. While you do so, here are a few stimulating items as well. Hope you have a smashing day and conquer the world. Catch you later…
Pfizer Drug Sales Drop And Spark Concern (Reuters)
Arena Diet Pill Unlikely To Cause Brain Tumors: Study (Bloomberg News)
Insurers Must Cover Birth Control With No Co-Pay (Associated Press)
Covance CEO Warns Post-M&A Integration Will Be Difficult (Outsourcing Pharma)
Pfizer To Lend Bankrupt Quigley Unit Up To $65M (Bloomberg News)
AstraZeneca Nexium-Aspirin Combo Gets EU OK (Pharma Times)
Prescriptions In England Soared Over The Past Decade (InPharm)
EDITOR’S NOTE: Please check this post for updates throughout the morning
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Arena Pharmaceuticals, AstraZeneca, Birth Control, Co-Pay, Covance, CRO, Diet Drugs, Diet Pills, England, Insurance Co-Pay, Lorcaserin, M&A, Nexium, Pfizer, Quigley, Weight-Loss Pills